Sandra Ramos-Alves active positions
| Companies | Position | Start | End |
|---|---|---|---|
| TURG POIN | Chief Executive Officer | 2022-08-16 | - |
| Director of Finance/CFO | 2022-08-31 | - | |
| MIRATI THERAPEUTICS | Director/Board Member | 2024-01-22 | - |
| President | 2024-01-22 | - | |
| Treasurer | 2024-01-22 | - | |
| RAYZEBIO, INC. | Director/Board Member | 2024-02-25 | - |
| Treasurer | 2024-02-25 | - | |
| KARA THER | Director/Board Member | 2024-03-17 | - |
| President | 2024-03-17 | - | |
| Treasurer | 2024-03-17 | - |
Career history of Sandra Ramos-Alves
Statistics
International
| United States | 5 |
Operational
| Director/Board Member | 3 |
| Treasurer | 3 |
| President | 2 |
Sectoral
| Health Technology | 5 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| RAYZEBIO, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
Karuna Therapeutics, Inc.
 Karuna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Sandra Ramos-Alves
- Experience